MeMed Diagnostics

Company Overview

Snapshot

Founded in June 2009 by Kfir Oved and Eran Eden, MeMed Diagnostics operates with 51–200 employees. The company has raised a total of $223.43 million across 11 funding rounds from 11 investors. In March 2026, Health Canada approved MeMed BV® on MeMed Key®, expanding the company's global footprint.

Business overview

MeMed Diagnostics develops and validates immune-based protein signatures to distinguish between bacterial and viral infections, aiming to combat resistant bacterial strains. Its core product, MeMed BV, is available in an ELISA format called ImmunoXpert, cleared for use in the EU, Switzerland, and Israel. The company is also advancing MeMed Key, a platform designed for rapid, central lab-precision measurement of multiple proteins and signatures, including MeMed BV, at the point of care. MeMed serves the healthcare industry, operating within the Health Tech & Life Sciences sector, specifically focusing on Digital Medical Diagnostics and Medical Devices.

Strategic signal

In March 2026, MeMed Diagnostics expanded its global reach with Health Canada's approval of MeMed BV® on MeMed Key®. This regulatory milestone signifies a critical validation of the company's diagnostic technology in a major North American market, indicating strong potential for increased adoption and market penetration for its rapid, accurate infection differentiation solutions.

Company Intelligence Q&A

What was a significant recent regulatory approval for MeMed Diagnostics?

In March 2026, Health Canada approved MeMed BV® on MeMed Key®, allowing MeMed Diagnostics to expand its global footprint.

What was a key partnership announced by MeMed Diagnostics?

In September 2020, DiaSorin and MeMed Diagnostics partnered to develop and commercialize a novel host immune response-based diagnostics solution.

When did MeMed Diagnostics receive FDA clearance for its infection test?

In September 2021, MeMed Diagnostics received 510(k) clearance from the FDA for MeMed BV for adults and children.

What was the latest disclosed funding round for MeMed Diagnostics?

In January 2022, MeMed Diagnostics raised $93 million to advance its immune system translation efforts.

Which healthcare service integrated MeMed BV into routine care?

In June 2022, Maccabi Healthcare Services became the first HMO globally to include the MeMed BV® test as part of its routine care.